News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

GTC Biotherapeutics develops and produces human therapeutic proteins through transgenic technology that provides production of therapeutic proteins in the milk of transgenic mammals. As of Dec 31 2006, Co.'s proprietary products and product candidates in development includes ATryn which is a recombinant form of human antithrombin; rhFVIIa which is a blood coagulation factor; rhAAT which is an inhibitor of elastase; and CD137 which is involved in the initiation and regulation of the human immune system. In addition, Co. has an external program under contract with Merrimack Pharmaceuticals, Inc., for transgenic production and purification of Merrimack's recombinant human alpha-fetoprotein.

Industry	Health
Sector	Biotechnology
# of Employees	143
Shares Outstanding	24.7M
Market Cap	18.1M
Enterprise Value	51.1M

52-Week High	$2.70
52-Week Low	$0.14
P/E Ratio	-5.21
EPS	-$0.14/shr
Dividend	-
Yield	-

Dr. Geoffrey F. Cox Ph.D.

Chief Executive Officer; Chairman; President

Mr. John B. Green

Chief Financial Officer; Senior Vice President; Treasurer

Mr. Gregory F. Liposky

Senior Vice President

Dr. Harry M. Meade Ph.D.

Senior Vice President

Mr. Richard A. Scotland

Senior Vice President

Mr. Daniel S. Woloshen

Senior Vice President; General Counsel

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Daily Market Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs